



**Northwest Biotherapeutics**  
("NWBT" or the "Company")

**'Additional Listing'**  
**Amendment**

**This is a replacement announcement for 'Holding in Company' RNS number 2471A posted on 30 July 2008.**

**The heading 'Holding in Company' has been replaced with a new heading of 'Additional Listing'. There are two additional paragraphs differentiating which shares are unrestricted and which are restricted of the 146,768 shares issued.**

**Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO.US),** announced it has issued 146,768 shares of common stock \$0.001 par value, representing 0.3466% of the issued share capital. The shares were issued in fulfillment of a US\$ 225,000 consideration for an option to acquire certain assets of MithraGen Corporation and in fulfillment of the exercise of certain employee stock options.

122,190 of the shares issued at \$0.001 par value are restricted and will be offered and sold outside the United States in reliance on Regulation S. These shares relate to the acquisition of an option to acquire certain assets of MithraGen Corporation.

24,578 of the shares issued at \$0.001 par value are unrestricted and will be eligible for settlement within CREST in the form of depository interests. These shares relate to the exercise of employee stock options.

The shares were issued as follows: 754 shares on 17 April 2008 at a price of \$2.267 per share; 122,190 shares on 17 June 2008 at \$1.8414 per share and 23,824 shares on 27 June 2008 at \$0.60 per share.

Application has been made for the shares to be admitted to trading on AIM on 5 August 2008.

**For further information, please contact:**

**Northwest Biotherapeutics**  
Anthony P. Deasey, Chief Financial Officer

+1 240-497-9024

For immediate release

July 31, 2008

**Buchanan Communications**

Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson /  
Catherine Breen

+44 (0)20 7466 5000

**Collins Stewart**

Adam Cowen/Tim Mickley

+44 (0)20 7523 8230